Skip to content

SINTERYX PHARMA

Bankruptcy closed on 28-10-2025 KBO/BCE: BE 0744.632.475

Curators

2 mandates
Curator, Herebaan-Oost 3/1, 3530 02 Houthalen-Helchteren
from 08-02-2024 to 28-10-2025
Also on 121 other cases
Curator, Lievehereboomstraat 118, 3720 Kortessem
from 08-02-2024 to 28-10-2025
Also on 116 other cases

Last board

1 director, no change since 2022
Director, permanent representative
since 02-03-2020
listed in the 2022 annual accounts, filed on 09-08-2023
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 04-03-2020
Permanent representatives 1
Permanent representative, for
appointed by deed of 17-02-2022

Office holders in the KBO →

Mandates through the years

2 names, the dashed line is today

Director

Director
BoardEarlierBankruptcy 08-02-2024
Mandates as a list
    • Director, from 02-03-2020, until the bankruptcy of 08-02-2024
    • Director, from 02-03-2020 to 17-02-2022

Control

Founder
This company
SINTERYX PHARMA
Equity -€115,606
Loss €134,631 in 2022

Capital

Capital
€2,500
Shares
100
Contribution per share
€25
Equity per share
-€1,156 in 2022
Source
deed of 04-03-2020

Articles of association

deed of 04-03-2020 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Second Monday of June at 19:00

Founder

At incorporation deed of 04-03-2020 ↗
  • sole founder · 100% at incorporation

Next steps